Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1174518 | 1.00 | CA1 (0.43) | CA1CA2CA7MEN1GAA | |
| SCHEMBL21746358 | 0.89 | CA1 (0.43) | CA1CA2CA7MEN1GAA | |
| SCHEMBL27285099 | 0.89 | CA1 (0.43) | CA1CA2CA7MEN1GAA | |
| SCHEMBL1726663 | 0.89 | CA1 (0.43) | CA1CA2CA7MEN1GAA | |
| SCHEMBL3484663 | 0.89 | CA1 (0.43) | CA1CA2CA7MEN1GAA | |
| SCHEMBL20456762 | 0.85 | CA1 (0.41) | CA1CA2CA7MEN1GAA | |
| SCHEMBL20456735 | 0.85 | CA1 (0.41) | CA1CA2CA7MEN1GAA | |
| SCHEMBL20456733 | 0.85 | CA1 (0.41) | CA1CA2CA7MEN1GAA | |
| SCHEMBL15898007 | 0.84 | GAA (0.33) | MEN1GAAKMT2A | |
| SCHEMBL83699 | 0.84 | CA2 (0.50) | CA1CA2CA7MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | FRONTIER BIOTECHNOLOGIES INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4098653-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021151265-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138310-A1 | PHARMACEUTICAL USE OF ALDEHYDE-BASED COMPOUND | ACE, ACE2, TMPRSS2 | CA1 1031/4885CA2 392/4885CA7 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.